**SUPPLEMENTAL MATERIAL FILE**

**Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers**

**Supplemental Table 1. Description of SARS-CoV-2 antigens coupled to Luminex MagPlex beads.**

|  |  |  |
| --- | --- | --- |
| **Source** | **Antigen** | **Cat. No.** |
| GenScript | Nucleoprotein | Z03480 |
| The Native Antigen Company | Nucleoprotein | REC31851 |
| GenScript | Nucleoprotein | Z03480 |
| Sino Biological | Spike S1 RBD | 40592-V08H |
| GenScript | RBD (h) | Z03483 |
| Mt. Sinai | RBD | n/a |
| Mt. Sinai | Whole spike | n/a |
| Sino Biological | S1+S2 ECD | 40589-V08B1 |

**Supplemental Table 2. Characteristics of the SARS-CoV-2 convalescent individuals who provided both plasma and saliva samples included in the analytical sample.**

|  |  |
| --- | --- |
|  | **Overall, n=101a** |
| Median age (IQR) | 44 (34-56) |
| Male, n (%) | 43 (42.6%) |
| Race, n (%) |  |
| Non-Hispanic White | 73 (72.3%) |
| Non-Hispanic Black | 9 (8.9%) |
| Hispanic | 3 (3.0%) |
| Non-Hispanic Asian | 9 (8.9%) |
| Other | 7 (6.9%) |
| Hospitalized, n (%) | 15 (14.9%) |
| Median days since PCR+ test (IQR) | 50 (40-70) |

aSample size that contributed to the complete case analysis.

**Supplemental Table 3. Concordance between each component of the multiplex SARS-Cov-2 antibody assay and the final algorithmic result of the multiplex salivary assay in COVID-19 convalescent individuals.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Salivary assaysa,b** | **Sum N/RBD/S S/CO, n = 101 (93+, 8-)** | | | |
| **PPA** | **NPA** | **PA** | **Kappa** |
| GenScript N | 54.8% | 100.0% | 58.4% | 0.161 |
| NAC N | 89.2% | 100.0% | 90.1% | 0.568 |
| Sino Bio RBD | 100.0% | 87.5% | 99.0% | 0.928 |
| Mt. Sinai RBD | 90.3% | 100.0% | 91.1% | 0.597 |
| GenScript RBD | 95.7% | 100.0% | 96.0% | 0.779 |
| Sino Bio ECD | 96.8% | 87.5% | 96.0% | 0.756 |
| Mt. Sinai S | 49.5% | 100.0% | 53.5% | 0.134 |
| Sum N S/COc | 89.2% | 100.0% | 90.1% | 0.568 |
| Sum RBD S/COd | 96.8% | 100.0% | 97.0% | 0.826 |
| Sum S S/COe | 89.2% | 87.5% | 89.1% | 0.507 |

Note: PPA: Positive Percent Agreement; NPA: Negative Percent Agreement; PA: Percent Agreement; Kappa: Cohen's Kappa Coefficient; nAb: Neutralizing antibody; NAC: Native Antigen Company; Sino Bio: Sino Biological.

aInsufficient total IgG, instrument error, ID discrepancy or other exclusion reasons for salivary assay were set to missing.

bEach saliva assay result was considered positive, if median fluorescence intensity (MFI) above threshold, and considered negative if MFI below threshold.

cSum N was considered positive if the sum of signal to cutoff ratios of 2 N antigens above threshold (mean plus 3 SD of pre-COVID samples).

dSum RBD was considered positive if the sum of signal to cutoff ratios of 3 RBD antigens above threshold (mean plus 3 SD of pre-COVID samples).

eSum S was considered positive if the sum of signal to cutoff ratios of 2 antigens above threshold (mean plus 3 SD of pre-COVID samples).

**Supplemental Table 4. Concordance between SARS-CoV-2 antibody tests of plasma from COVID-19 convalescent individuals.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **PPA** | **NPA** | **PA** | **Kappa** |
|  | Ortho Vitros (88+, 13-) | | | |
| Euroimmun | 100.0% | 84.6% | 98.0% | 0.906 |
| BioRad | 95.5% | 61.5% | 91.1% | 0.589 |
| nAb | 75.0% | 76.9% | 75.2% | 0.320 |
|  | nAb (69+, 32-) | | | |
| Euroimmun | 98.6% | 31.3% | 77.2% | 0.362 |
| BioRad | 95.7% | 28.1% | 74.3% | 0.286 |
|  | Euroimmun (90+, 11-) | | | |
| BioRad | 94.4% | 63.6% | 91.1% | 0.559 |

Note: PPA: Positive Percent Agreement; NPA: Negative Percent Agreement; PA: Percent Agreement; Kappa: Cohen's Kappa Coefficient; nAb: Neutralizing antibody. nAb area under curve (AUC) <20 was considered as negative result, ≥20 as positive result. Indeterminate results for blood antibody tests were considered negative.

**Supplemental Table 5. Spearman’s rank correlation between the net median fluorescence intensity of multiplex salivary SARS-CoV-2 antibody assay and plasma serologic assay signal to cut-off ratio (S/CO) in COVID-19 convalescent individuals.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Salivary assaysa** | **Ortho Vitros S/CO** | | **Euroimmun AU** | | **BioRad OD** | | **nAb AUC** | |
| **Spearman coefficient**  **(95% CI)b** | ***p* value** | **Spearman coefficient**  **(95% CI)b** | ***p* value** | **Spearman coefficient**  **(95% CI)b** | ***p* value** | **Spearman coefficient**  **(95% CI)b** | ***p* value** |
| GenScript N | 0.58 (0.42, 0.72) | <0.001 | 0.58 (0.43, 0.71) | <0.001 | 0.52 (0.34, 0.66) | <0.001 | 0.57 (0.41, 0.69) | <0.001 |
| NAC N | 0.63 (0.48, 0.75) | <0.001 | 0.62 (0.47, 0.74) | <0.001 | 0.57 (0.41, 0.71) | <0.001 | 0.63 (0.48, 0.74) | <0.001 |
| Sino Bio RBD | 0.85 (0.76, 0.91) | <0.001 | 0.83 (0.73, 0.89) | <0.001 | 0.41 (0.22, 0.57) | <0.001 | 0.77 (0.67, 0.84) | <0.001 |
| Mt. Sinai RBD | 0.83 (0.73, 0.90) | <0.001 | 0.80 (0.71, 0.87) | <0.001 | 0.39 (0.19, 0.55) | <0.001 | 0.75 (0.65, 0.83) | <0.001 |
| GenScript RBD | 0.86 (0.77, 0.92) | <0.001 | 0.83 (0.75, 0.89) | <0.001 | 0.40 (0.20, 0.56) | <0.001 | 0.77 (0.67, 0.85) | <0.001 |
| Sino Bio ECD | 0.63 (0.47, 0.75) | <0.001 | 0.61 (0.46, 0.73) | <0.001 | 0.38 (0.19, 0.54) | <0.001 | 0.62 (0.48, 0.73) | <0.001 |
| Mt. Sinai S | 0.81 (0.71, 0.88) | <0.001 | 0.79 (0.69, 0.86) | <0.001 | 0.44 (0.24, 0.59) | <0.001 | 0.76 (0.65, 0.84) | <0.001 |
| Sum N S/COc | 0.62 (0.46, 0.74) | <0.001 | 0.62 (0.46, 0.73) | <0.001 | 0.57 (0.41, 0.71) | <0.001 | 0.62 (0.47, 0.72) | <0.001 |
| Sum RBD S/COd | 0.86 (0.76, 0.91) | <0.001 | 0.83 (0.74, 0.89) | <0.001 | 0.41 (0.22, 0.57) | <0.001 | 0.77 (0.66, 0.85) | <0.001 |
| Sum S S/COe | 0.68 (0.53, 0.79) | <0.001 | 0.66 (0.52, 0.77) | <0.001 | 0.40 (0.20, 0.56) | <0.001 | 0.67 (0.54, 0.77) | <0.001 |
| Sum N/S/RBD S/COf | 0.80 (0.69, 0.87) | <0.001 | 0.77 (0.68, 0.85) | <0.001 | 0.44 (0.26, 0.59) | <0.001 | 0.75 (0.65, 0.83) | <0.001 |

Note: S/CO = signal to cut off ratio. AU = arbitrary units. OD = optical density. nAb = neutralizing antibody. AUC: area under curve. CI: confidence interval. NAC: Native Antigen Company. Sino Bio: Sino Biological.

aSalivary assay values were signal to cutoff.

bSpearman’s correlation coefficients (ρ) were calculated with 95% CI estimated over 1000 bootstrap iterations.

cSum of S/CO of 2 N antigens.

dSum of S/CO of 3 RBD antigens.

eSum of S/CO of 2 Spike antigens.

fSum of 7 N, RBD and S antigen S/CO.

**Supplemental Table 6. Spearman’s rank correlation between SARS-CoV-2 antibody tests of plasma from COVID-19 convalescent individuals.**

|  |  |  |
| --- | --- | --- |
|  | **Spearman coefficient (95% CI)** | ***p* value** |
|  | Ortho, S/CO | |
| Euroimmun AU | 0.93 (0.90, 0.95) | <0.001 |
| BioRad OD | 0.43 (0.23, 0.59) | <0.001 |
| nAb AUC | 0.83 (0.74, 0.89) | <0.001 |
|  | nAb | |
| Euroimmun AU | 0.80 (0.72, 0.86) | <0.001 |
| BioRad OD | 0.38 (0.18, 0.55) | <0.001 |
|  | Euroimmun AU | |
| BioRad OD | 0.45 (0.26, 0.61) | <0.001 |

Note: S/CO = signal to cut off ratio. AU = arbitrary units. OD = optical density. nAb = neutralizing antibody. AUC: area under curve. CI: confidence interval.

Spearman’s correlation coefficients (ρ) were calculated with 95% CI estimated over 1000 bootstrap iterations.